Show simple item record

dc.contributor.authorMabeya, Sepha
dc.contributor.authorNyamache, Anthony
dc.contributor.authorNgugi, Caroline
dc.contributor.authorNyerere, Andrew
dc.contributor.authorLihana, Raphael
dc.date.accessioned2021-09-20T13:10:51Z
dc.date.available2021-09-20T13:10:51Z
dc.date.issued2020
dc.identifier.citationSepha, M., Anthony, N., Caroline, N., Andrew, N., & Raphael, L. (2020). Characterization of HIV-1 integrase gene and resistance associated mutations prior to roll out of integrase inhibitors by Kenyan National HIV-Treatment Program in Kenya. Ethiopian journal of health sciences, 30(1).en_US
dc.identifier.issneISSN: 1029-1857
dc.identifier.issnprint 1029-1857
dc.identifier.urihttps://www.ajol.info/index.php/ejhs/article/view/195682
dc.identifier.urihttp://ir-library.ku.ac.ke/handle/123456789/22543
dc.descriptionA research article published in Ethiopian Journal of Health Sciencesen_US
dc.description.abstractBACKGROUND: Antiretroviral therapy containing an integrase strand transfer inhibitor plus two Nucleoside Reverse Transcriptase inhibitors has now been recommended for treatment of HIV-1-infected patients. This thus determined possible pre-existing integrase resistance associated mutations in the integrase gene prior to introduction of integrase inhibitors combination therapy in Kenya. METHODS: Drug experienced HIV patients were enrolled at Kisii Teaching and Referral in Kenya. Blood specimens from (33) patients were collected for direct sequencing of HIV-1 polintegrase genes. Drug resistance mutations were interpreted according to the Stanford algorithm and phylogenetically analysed using insilico tools. RESULTS: From pooled 188 Kenyan HIV integrase sequences that were analysed for drug resistance, no major mutations conferring resistance to integrase inhibitors were detected. However, polymorphic accessory mutations associated with reduced susceptibility of integrase inhibitors were observed in low frequency; M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), G140S/A/C (1.1%) and E157Q (0.5%). Phylogenetic analysis (330 sequences revealed that HIV-1 subtype A1 accounted for majority of the infections, 26 (78.8%), followed by D, 5 (15.2%) and C, 2 (6%). CONCLUSION: The integrase inhibitors will be effective in Kenya where HIV-1 subtype A1 is still the most predominant. However, occurring polymorphisms may warrant further investigation among drug experienced individuals on dolutegravir combination or integrase inhibitor treatment.en_US
dc.description.sponsorshipAfrica-ai-Japanen_US
dc.language.isoenen_US
dc.publisherJimma Universityen_US
dc.subjectIntegraseen_US
dc.subjectDolutegraviren_US
dc.subjectMutationsen_US
dc.subjectResistanceen_US
dc.titleCharacterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenyaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record